Cardiff Oncology to Present at Upcoming Investor Conferences in September

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology firm, announced its participation in two upcoming virtual investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, and the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021. During these events, CEO Mark Erlander and CFO James Levine will engage in presentations and one-on-one meetings. Cardiff is focused on developing onvansertib, a novel cancer treatment targeting unmet medical needs, particularly in KRAS-mutated cancers.

SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that Mark Erlander, Ph.D., chief executive officer and James Levine, chief financial officer, of Cardiff Oncology, will present and participate in virtual 1x1 investor meetings at the H.C. Wainwright 23^rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference, taking place September 13 – 15^th 2021, and September 27 – 30^th 2021, respectively.

Details on the presentations can be found below.

H.C. Wainwright 23rd Annual Global Investment Conference
Presentation Date:	Available on-demand starting at 7:00 AM ET on September 13, 2021
Webcast Link:	https://journey.ct.events/view/50ff15c3-cb28-455a-bf01-6e3b2c0dcfce

 

2021 Cantor Virtual Global Healthcare Conference
Presentation Date:	Thursday, September 30, 2021
Time:	2:40 – 3:10 PM ET
Webcast Link:	https://wsw.com/webcast/cantor12/crdf/2059190

Replays of the presentations will be available by visiting the "Events" section of the Cardiff Oncology website after their conclusion and will be archived for 90 days.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 ("PLK1") inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to refine assessment of patient response to treatment. We have three clinical programs currently ongoing: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castrate-resistant prostate cancer (mCRPC); and a Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). For more information, please visit https://www.cardiffoncology.com.  

Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652 
vkelemen@cardiffoncology.com 

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569 
jallaire@lifesciadvisors.com 

Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192 
ajobe@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september-301370033.html

SOURCE Cardiff Oncology, Inc.

FAQ

What is Cardiff Oncology's stock symbol?

Cardiff Oncology trades under the stock symbol CRDF.

When will Cardiff Oncology present at the H.C. Wainwright conference?

Cardiff Oncology will present at the H.C. Wainwright conference starting at 7:00 AM ET on September 13, 2021.

What is the focus of Cardiff Oncology's research?

Cardiff Oncology focuses on developing precision medicine treatments for cancers with high unmet medical need, including KRAS-mutated colorectal cancer.

When is the 2021 Cantor Virtual Global Healthcare Conference?

The 2021 Cantor Virtual Global Healthcare Conference will take place on September 30, 2021.

Who will represent Cardiff Oncology at the investor conferences?

CEO Mark Erlander and CFO James Levine will represent Cardiff Oncology at the upcoming investor conferences.

Where can I watch Cardiff Oncology's conference presentations?

Cardiff Oncology's presentations can be accessed via their website's Events section after the conferences.